Search Results

September 2024: Test Update – Vasoactive Intestinal Polypeptide (VIP), Plasma

Sept 2024: Immediate Test Change – Testosterone, Free and Total

Beginning September 12, 2024, Testosterone, Free and Total (TFTEST) will be sent to a different reference laboratory due to reagent problems.

July 2024: Blood Culture Bottle Shortage

Register Now! 2025 Cleveland Clinic Multispecialty Pathology Symposium

June 2024: Test Update – Vasoactive Intestinal Polypeptide (VIP), Plasma

Test Discontinuation: Creatine Kinase-Myocardial Band

CKMB is an antiquated cardiac marker due to its limited clinical utility. Current guidelines recommend cardiac troponin testing.  

New Test: Alzheimer’s Disease Biomarker Panel, Cerebrospinal Fluid

This test measures p-Tau181, Total-Tau, and β-Amyloid in cerebrospinal fluid (CSF) from adult patients 55 years of age and older.

January 2024: Send-Out Test Delays Caused by Weather

November 2023: Product Discontinuation – BD CultureSwab™

The eSwab™ (Copan Diagnostics) collection device—utilized by Cleveland Clinic for 8+ years—will now be the primary swab for bacteriology.

November 2023: Test Update – Chromogranin A, New Assay

November 2023: Test Delay – Oxalate, Plasma and Oxalate, 24-hour Urine

2024 Cleveland Clinic Laboratories Soft Tissue Pathology Course – Registration Now Open

This four-day course is a one-of-a-kind experience in one of the country’s busiest soft tissue pathology consultation practices.

September 2023: Changes to Reference Ranges – Catecholamines, Fractionated, Plasma (PLCAT)

Changes are effective October 2, 2023. For more information, please contact Client Services for assistance.

August 2023: Test Discontinuation – HIV-1 Western Blot (HIV1CO)

As an alternative, Cleveland Clinic Laboratories recommends HIV-1 p24 Ag + HIV-1-2 Ab, with reflex to differentiation (HIV12C) testing.

July 2023: Updates to COMAP, DRGTOF, MECDRG, TAPENU, and UASFR

All changes are effective August 21, 2023. For more information, please contact Client Services for assistance.

July 2023: Updates to Genital & Sexual Health Specimen Collection

July 2023: Updates to Recommended Myelodysplastic Syndrome Testing

In keeping with the NCCN guidelines, Chromosome Analysis with Reflex to FISH (CHRMDS) is the recommended test for MDS.

Cleveland Clinic and LabConnect Announce Strategic Alliance

This new strategic alliance will accelerate clinical trials and connect patients to new medicines for improved patient care.

CC-SIGN Targeted Oncology Panel by Next-Generation Sequencing

CC-SIGN® Targeted Oncology Panel (TOP) by Next-Generation Sequencing

This custom 59-gene NGS panel identifies SNVs, indels, CNVs from DNA, and fusion transcripts, and aberrant transcripts from RNA.

May 2023: Discontinued – Natural Killer Cells, Functional (NKFUNC)

May 2023: New Test – Clozapine (CLOZA)

May 2023: COVID-19 Testing – CPT Code Update

May 2023: Changes to Legionella Diagnostic Testing (LEGPCR)

April 2023: Updates to H. pylori Urea Breath Test

2024 Cleveland Clinic Multispecialty Pathology Symposium – Register Now!

Join us for the 2024 Cleveland Clinic Multispecialty Pathology Symposium, January 26-28, 2024, at the Wynn Las Vegas.

February 2023: Send-out Test Discontinuation – T3 Uptake (T3U)

Changes are effective February 21, 2023. If you have any questions about these changes, please contact Client Services for assistance.

December 2022: Changes to Acceptable Tube Type for Azole Anti-Fungal Therapeutic Drug Monitoring

All changes are effective December 20, 2022. If you have any questions about these changes, please contact Client Services for assistance.

Pathology Insights: Tumors of the Lung with Sanjay Mukhopadhyay, MD

In this video, Sanjay Mukhopadhyay, MD, briefly covers all lung tumor types listed in the new (2021) World Health Organization classification.

August 2022: Changes to C Telopeptide, Beta Cross Linked (CTELO)

Changes are effective as of September 6, 2022. For more information, please contact Client Services for assistance.

September 2022: Best Practice for Detecting Hyperhomocysteinemia – Homocysteine Testing—Not MTHFR Genotyping

If there is a clinical concern regarding hyperhomocysteinemia, CCL recommends Homocysteine testing (HOMCYS) in place of MTHFR genotyping.

Pathology Insights: Update on Small Round Cell Tumors with Scott Kilpatrick, MD

In this video, Dr. Kilpatrick provides context and WHO updates on the evolving classification of undifferentiated round cell sarcomas.

July 2022: Test Delay – Testosterone, Total and Free, Serum (TFTEST)

Effective July 18, 2022, Testosterone, Total and Free, Serum (TFTEST) testing is currently delayed for approximately three weeks.

July 2022: Changes to Sulfonylurea Hypoglycemics (SULFON)

Changes are effective as of July 5, 2022. For more information, please contact Client Services for assistance.

June 2022: Changes to Testosterone, Total and Free, Serum (TFTEST)

Changes are effective as of June 30, 2022. For more information, please contact Client Services for assistance.

May 2022: Immediate Test Discontinuation – Giardia lamblia IgG, IgA, IgM (GIAGAM)

Giardia lamblia IgG, IgA, IgM (GIAGAM) testing has been discontinued by the performing reference laboratory effective May 16, 2022.

May 2022: Test Discontinuation – Legionella Testing, LEGMAB & SLEGAB

LEGMAB and SLEGAB will be discontinued effective May 2, 2022. For more information, please contact Client Services for assistance.

Test Delay: Alpha 1 Antitrypsin Phenotype (A1APHE)

Test delay announcement effective April 14, 2022. For more information, please contact Client Services for assistance.

April 2022: Changes to CTELO, MECDS9, and K2 Testing

All changes are effective May 16, 2022. For more information, please contact Client Services for assistance.

March 2022: Changes to CBCDIF Result Reporting; Aldosterone Reference Intervals

Several changes impacting CBCDIF, ALDO, RENIND, and ALDREN testing are effective as of February 28, 2022. Read more for details.

February 2022: Immediate Test Discontinuation – Digoxin, Free, Serum (DIGFR)

Due to supply issues, Digoxin, Free, Serum (DIGFR) testing is temporarily discontinued effective February 28, 2022.

Estimated Glomerular Filtration Rate (eGFR) Updates

Recently released recommendations affecting a race variable in eGFR reporting have resulted in changes at Cleveland Clinic.

February 2022: Changes to Mycoplasma genitalium (MYGPCR)

Any additional information will be included in a future Technical Update. If you have any questions, please contact Client Services.

February 2022: Epic Beaker LIS Go-Live at Cleveland Clinic

On Saturday, February 26, 2022, Cleveland Clinic Laboratories will transition to the Epic Beaker laboratory information system (LIS).

January 2022: Changes to Specimen Requirements, Reference Ranges, and More

All changes are effective February 22, 2022. For more information, please contact Client Services for assistance.

December 2021: Test Delay – HIV-1 Antibody Confirmation by Western Blot (HIV1CO)

HIV-1 by Western Blot (HIV1CO) testing is experiencing extended test delays caused by a nationwide shortage of testing kits.

October 2021: Limited Availability of Amies Dual Swabs, ESwabs™

Intermittent supply chain interruptions are anticipated for Amies Dual Swabs and ESwabs™ through early 2022.

October 2021: TFTEST – Temporary Change in Performing Send-out Laboratory

Beginning October 25, 2021, Testosterone, Total and Free, Serum (TFTEST) will be temporarily sent to an alternate reference laboratory.

September 2021: New Test – Beta(β)-D-Glucan Assay

This FDA-approved assay diagnoses certain systemic fungal infections and supports anti-fungal therapy responses in hospitalized patients.

September 2021: Ziad Peerwani, MD Appointed as Medical Director of Cleveland Clinic Laboratories

Ziad Peerwani, MD has been appointed as the new Medical Director for Cleveland Clinic Laboratories, effective September 1, 2021.